#United States #New York #FDA #Pomerantz LLP #PepGen

Investor Alert: Pomerantz Law Firm Investigates PepGen Inc.

Pomerantz LLP, a notable legal firm, has taken a significant step in investigating potential claims brought by investors of PepGen Inc. (NASDAQ: PEPG). The firm has prompted investors to make contact if they believe they were misled about the company's practices or securities performance. This inquiry primarily revolves around serious allegations of securities fraud and unlawful business behaviors potentially engaged by PepGen and certain executives within the company.

Background Context

On March 4, 2026, PepGen published a press release revealing that the U.S. Food and Drug Administration (FDA) had imposed a partial clinical hold on its FREEDOM2-DM1 Phase 2 multiple ascending dose (MAD) trial, which was centered on the drug PGN-EDODM1 aimed at treating myotonic dystrophy type 1 (DM1). The hold stemmed from questions raised concerning preclinical studies, specifically related to pharmacology and toxicology.

The immediate aftermath of this announcement proved detrimental to investor confidence. On March 5, 2026, in response to the news, PepGen's stock plummeted by $1.25, a steep 18.57% decline, closing the day at $5.50 per share. This drop not only affected the company's market standing but also raised eyebrows among investors regarding the overall integrity of PepGen's operations and transparency.

Interestingly, the saga continued when on March 30, 2026, PepGen released data from the 5 mg/kg cohort of the ongoing Phase 2 trial. Despite the company labeling the findings as 'promising', analysts were quick to highlight the minimal progress observed in primary endpoints like handgrip strength and mobility tests. Consequently, this half-hearted optimism led to yet another plunge for PepGen's stock, which saw a staggering decrease of $2.46 or 58.16%, finishing at $1.77 per share on March 31, 2026. Such volatility raises significant concerns about the company's ability to provide substantial advancements in drug efficacy and patient outcomes.

The Role of Pomerantz LLP

Pomerantz LLP is widely regarded for its advocacy on behalf of investors and has a long-standing reputation in the realm of corporate, securities, and antitrust class litigation. Founded by Abraham L. Pomerantz, often referred to as the dean of class action law, the firm has dedicated over 85 years to defending the rights of those who believe they have been victims of corporate misconduct. The firm aims to recover damages on behalf of aggrieved investors and has successfully handled numerous high-profile cases. Their investigations arise not only from the implications of PepGen's drug trial data but also from the broader context of trust that investors place in public companies.

Individuals who identify with PepGen shareholders and believe they may have been impacted by the alleged securities fraud are encouraged to reach out to Pomerantz LLP for further assistance. The firm's probing may illuminate critical truths about PepGen's business practices and transparency, which are vital for maintaining investor relations and public confidence in biomedical innovations.

Conclusion

As this situation unfolds, it remains essential for current and prospective investors in PepGen Inc. to stay informed of developments. It serves as a reminder of the inherent risks associated with investment in medical biotechnology, where regulatory actions and clinical outcomes can drastically influence stock valuations. Vigilance and legal support can help protect the interests of investors seeking recourse in this turbulent market landscape. For those keen to learn more or participate in potential action against the company, contacting Pomerantz LLP might prove to be an important step towards accountability.